Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm

Clinical and Experimental Ophthalmology

Volumn 38, Issue 7, 2010, Pages 688-691

  Cannon, Paul S ^a   MacKenzie, Kenneth R ^a   Cook, Anne E ^a   Leatherbarrow, Brian ^a  

^a MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

Author keywords

Benign essential blepharospasm; Botulinum toxin; Hemifacial spasm; Response comparison; Treatment satisfaction

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; BENIGN ESSENTIAL BLEPHAROSPASM; BLEPHAROSPASM; CLINICAL TRIAL; DRUG EFFECT; EYE SURGERY; FEMALE; HEMIFACIAL SPASM; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; STRUCTURED QUESTIONNAIRE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BLEPHAROSPASM; BOTULINUM TOXINS, TYPE A; FEMALE; HEMIFACIAL SPASM; HUMANS; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; QUESTIONNAIRES;

EID: 77958505158     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2010.02303.x     Document Type: Article

References (15)

1. O'Day J. Use of botulinum toxin in neuro-ophthalmology. Curr Opin Ophthalmol 2001; 12: 419-22.
2. Scott AB, Kennedy EG, Stubbs HA. Botulinum toxin as a treatment for blepharospasm. Arch Ophthalmol 1985; 103: 347-50.
3. Elston JS. Botulinum toxin treatment of hemifacial spasm. J Neurol Neurosurg Psychiatry 1986; 49: 827-9.
4. Crow R, Gage H, Hampson S et al. The measurement of satisfaction with healthcare: implications for practice from a systemic review of the literature. Health Technol Assess 2002; 6: 32.
5. Costa J, Espirito-Santo C, Borges A et al. Botulinum toxin type A for blepharospasm. Cochrane Database Syst Rev 2005; 25: CD004900.
6. Hall TA, McGwin G, Searcey K et al. Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol 2006; 124: 116-19.
7. Drummond GT, Hinz BJ. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time. Can J Ophthalmol 2001; 36: 398-403.
8. Shorr N, Seiff SR, Kopelman J. The use of botulinum toxin in blepharospasm. Am J Ophthalmol 1985; 99: 542-54.
9. Mauriello JA, Aljian J. Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years. Br J Ophthalmol 1991; 75: 737-9.
10. Cetinkaya A, Brannan PA. What is new in the era of focal dystonia treatment? Botulinum injections and more. Curr Opin Ophthalmol 2007; 18: 424-9.
11. Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. Ophthal Plast Reconstr Surg 1998; 14: 305-17.
12. Ortisi E, Henderson HWA, Bunce C et al. Blepharospasm and hemifacial spasm; a protocol for titration of botulinum toxin dose to the individual patient and for management of refractory cases. Eye 2006; 20: 916-22.
13. Elibol O, Ozkan B, Hekimhan PK, Caglar Y. Efficacy of skin cooling and EMLA cream application for pain relief of periocular botulinum toxin injection. Ophthal Plast Reconstr Surg 2007; 23: 130-3.
14. Sami MS, Soparkar CNS, Patrinely JR et al. Efficacy of botulinum toxin type A after topical anaesthesia. Ophthal Plast Reconstr Surg 2006; 22: 448-52.
15. Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: review of 264 patients. J Neurol Neurosurg Psychiatry 1988; 51: 767-72.